616 related articles for article (PubMed ID: 25461655)
21. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
[No Abstract] [Full Text] [Related]
22. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
23. Comparison of in vitro synergy between polymyxin B or colistin in combination with 16 antimicrobial agents against multidrug-resistant Acinetobacter baumannii isolates.
Wang Y; Ma Y; Xiong L; Wang X; Zhou Y; Chi X; Chen T; Fu H; Luo Q; Xiao Y
J Microbiol Immunol Infect; 2024 Apr; 57(2):300-308. PubMed ID: 38350840
[TBL] [Abstract][Full Text] [Related]
24. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].
Akin FE; Bayram A; Balci I
Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954
[TBL] [Abstract][Full Text] [Related]
26. Antibiotic Resistance Pattern Of Acinetobacter Baumannii Isolated From Bacteremia Patients In Pakistan.
Jabeen F; Khan Z; Sohail M; Tahir A; Tipu I; Murtaza Saleem HG
J Ayub Med Coll Abbottabad; 2022; 34(1):95-100. PubMed ID: 35466635
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
28. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
Cai Y; Chai D; Wang R; Liang B; Bai N
J Antimicrob Chemother; 2012 Jul; 67(7):1607-15. PubMed ID: 22441575
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand.
Koomanachai P; Tiengrim S; Kiratisin P; Thamlikitkul V
Int J Infect Dis; 2007 Sep; 11(5):402-6. PubMed ID: 17291803
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR
Pan S; Huang X; Wang Y; Li L; Zhao C; Yao Z; Cui W; Zhang G
Antimicrob Resist Infect Control; 2018; 7():8. PubMed ID: 29387342
[TBL] [Abstract][Full Text] [Related]
31. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
33. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection.
Chen Z; Chen Y; Fang Y; Wang X; Chen Y; Qi Q; Huang F; Xiao X
Sci Rep; 2015 Nov; 5():17091. PubMed ID: 26597507
[TBL] [Abstract][Full Text] [Related]
35. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):431-4. PubMed ID: 19733029
[TBL] [Abstract][Full Text] [Related]
36. Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.
Smith NM; Lenhard JR; Boissonneault KR; Landersdorfer CB; Bulitta JB; Holden PN; Forrest A; Nation RL; Li J; Tsuji BT
Clin Microbiol Infect; 2020 Sep; 26(9):1207-1213. PubMed ID: 32061797
[TBL] [Abstract][Full Text] [Related]
37. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
Ceccarelli G; Oliva A; d'Ettorre G; D'Abramo A; Caresta E; Barbara CS; Mascellino MT; Papoff P; Moretti C; Vullo V; Visca P; Venditti M
BMC Infect Dis; 2015 Sep; 15():393. PubMed ID: 26424078
[TBL] [Abstract][Full Text] [Related]
38. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
[TBL] [Abstract][Full Text] [Related]
39. Polymyxin Resistance Mechanisms: From Intrinsic Resistance to Mcr Genes.
Meletis G; Skoura L
Recent Pat Antiinfect Drug Discov; 2018; 13(3):198-206. PubMed ID: 30474535
[TBL] [Abstract][Full Text] [Related]
40. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway.
Sampson TR; Liu X; Schroeder MR; Kraft CS; Burd EM; Weiss DS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5642-9. PubMed ID: 22908157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
